In vivo treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis

Clin Exp Immunol. 2007 May;148(2):373-81. doi: 10.1111/j.1365-2249.2007.03350.x.


Recently we demonstrated that in inflammatory bowel disease (IBD) macrophage-oxidative burst activity is increased and NADPH oxidase mRNA is induced. The herbal phenylethanoid acteoside isolated from Plantago lanceolata L. was shown to exhibit anti-oxidative potential. Using the dextran sulphate sodium (DSS)-induced colitis model, in this study we have assessed whether systemic application of acteoside affects colitis. Colitis was induced by DSS in Balb/c mice. Treatment with acteoside (120, 600 microg/mouse/day) was performed intraperitoneally. The colon lengths were determined. Colonic tissue was scored histologically (max. score 8) by a blinded investigator. T cells isolated from mesenteric lymph nodes (MLN) were stimulated with anti-CD3 antibody in the presence of interleukin (IL)-2 (final concentration 10 U/ml). After incubation for 24 h, IL-1beta, IL-6, IL-12 tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma levels in supernatants were analysed by the beadlyte cytokine detection system. Histological scoring of colonic tissue revealed that application of acteoside was followed by a significantly improved histological score. In acute colitis the histological score was 3.2 with acteoside versus 5.2 with phosphate-buffered saline (PBS) (P < 0.02). In chronic colitis both 120 microg (3.3 versus 5.2) or 600 microg acteoside (3.0 versus 5.2) significantly ameliorated colitis (both P < 0.02). Stimulated MLN from mice with chronic DSS-induced colitis treated with acteoside showed a significant down-regulation of IFN-gamma secretion (195 pg/ml with 600 microg acteoside versus 612 pg/ml with PBS, P < 0.02). Inhibition of oxidative burst activity with acteoside reduced mucosal tissue damage in DSS colitis and could be a therapeutic alternative for IBD treatment. Further studies of this agent are warranted.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Animals
  • Antioxidants / therapeutic use*
  • Chronic Disease
  • Colitis / chemically induced
  • Colitis / drug therapy*
  • Colitis / immunology
  • Colitis / pathology
  • Colon / immunology
  • Cytokines / metabolism
  • Dextran Sulfate
  • Enzyme-Linked Immunosorbent Assay / methods
  • Female
  • Glucosides / therapeutic use*
  • Inflammation Mediators / metabolism
  • Intestinal Mucosa / immunology
  • Lymph Nodes / immunology
  • Macrophages / immunology
  • Mice
  • Mice, Inbred BALB C
  • Peroxidase / metabolism
  • Phenols / therapeutic use*
  • Respiratory Burst / drug effects
  • Weight Loss / drug effects


  • Antioxidants
  • Cytokines
  • Glucosides
  • Inflammation Mediators
  • Phenols
  • acteoside
  • Dextran Sulfate
  • Peroxidase